Eli Lilly and Company (VIE:LLYC)

Market Cap	628.11B
Revenue (ttm)	45.35B
Net Income (ttm)	11.75B
Shares Out	n/a
EPS (ttm)	13.02
PE Ratio	53.45
Forward PE	29.33
Dividend	5.29 (0.76%)
Ex-Dividend Date	Aug 15, 2025

Volume	40
Average Volume	50
Open	699.00
Previous Close	696.80
Day's Range	694.10 - 705.10
52-Week Range	539.10 - 887.00
Beta	n/a
RSI	55.04
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: LLYC

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD